Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Chief Financial Officer | February 18, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date February 18, 2026 · Filed March 03, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 731,312 |
Last balance in matching sequence
After 2026-02-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-02-18 · Grant · Acquired 44,040 · Balance 745,999 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Row 2 · 2026-02-18 · Tax withholding · Disposed 14,687 · Balance 731,312 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 111,358 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000060 · form4.xml · derivative · entry 4 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,358 Underlying: Class A Common Stock · 111,358 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 14,541 | $3.84 | $55,837.44 |
DisclosureSEC source: 0002064832-26-000060 · form4.xml · nonDerivative · entry 3 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731,020 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 43,602 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000060 · form4.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 745,561 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 195,312 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000060 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 701,959 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:34 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 14,687 | $3.84 | $56,398.08 |
DisclosureSEC source: 0002064832-26-000088 · form4a.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731,312 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:34 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 44,040 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000088 · form4a.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 745,999 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 13,769 | $3.73 | $51,358.37 |
DisclosureSEC source: 0002064832-26-000031 · form4.xml · nonDerivative · entry 4 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,647 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 13,369 | $3.73 | $49,866.37 |
DisclosureSEC source: 0002064832-26-000031 · form4.xml · nonDerivative · entry 3 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,416 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 21,412 | $3.73 | $79,866.76 |
DisclosureSEC source: 0002064832-26-000031 · form4.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,785 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,898 | $3.73 | $14,539.54 |
DisclosureSEC source: 0002064832-26-000031 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 555,197 Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:49 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 170,841 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003224 · form4.xml · derivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,841 Underlying: Class A Common Stock · 170,841 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:49 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 165,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003224 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559,095 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 00:17 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 804 | $3.70 | $2,974.80 |
DisclosureSEC source: 0001062993-25-002931 · form4.xml · nonDerivative · entry 4 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,939 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:17 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 2,960 | $3.70 | $10,952.00 |
DisclosureSEC source: 0001062993-25-002931 · form4.xml · nonDerivative · entry 3 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,743 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:17 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 19,528 | $3.70 | $72,253.60 |
DisclosureSEC source: 0001062993-25-002931 · form4.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,703 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:17 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 11,765 | $3.70 | $43,530.50 |
DisclosureSEC source: 0001062993-25-002931 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,231 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:24 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 289,915 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-24-004314 · form4.xml · derivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,915 Underlying: Class A Common Stock · 289,915 shares Expires 2034-02-21 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:24 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 160,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004314 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,996 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 804 | $3.48 | $2,797.92 |
DisclosureSEC source: 0001062993-24-003761 · form4.xml · nonDerivative · entry 3 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,646 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,513 | $3.68 | $12,927.84 |
DisclosureSEC source: 0001062993-24-003761 · form4.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,450 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 18,966 | $3.68 | $69,794.88 |
DisclosureSEC source: 0001062993-24-003761 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,963 Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:49 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 287,892 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001062993-23-004888 · form4.xml · derivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,892 Underlying: Class A Common Stock · 287,892 shares Expires 2033-02-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:49 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 242,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004888 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,929 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:24 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 953 | $2.75 | $2,620.75 |
DisclosureSEC source: 0001062993-23-004055 · form4.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,421 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:24 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,506 | $2.92 | $10,237.52 |
DisclosureSEC source: 0001062993-23-004055 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,374 Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 23:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 953 | $7.78 | $7,414.34 |
DisclosureSEC source: 0001062993-22-004796 · form4.xml · nonDerivative · entry 3 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,880 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 95,692 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001062993-22-004796 · form4.xml · derivative · entry 4 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,692 Underlying: Class A Common Stock · 95,692 shares Expires 2032-02-15 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 1,876 | $8.03 | $15,064.28 |
DisclosureSEC source: 0001062993-22-004796 · form4.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,833 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 40,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004796 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,709 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2022. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:58 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 83,955 | $0.00 Strike: $13.68 | $0.00 |
DisclosureSEC source: 0001661181-21-000035 · edgar.xml · derivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,955 Underlying: Class A Common Stock · 83,955 shares Expires 2031-02-16 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:58 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 10,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-21-000035 · edgar.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,361 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 02:47 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 43,239 | $0.00 Strike: $12.74 | $0.00 |
DisclosureSEC source: 0001661181-21-000017 · edgar.xml · derivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,239 Underlying: Class A Common Stock · 43,239 shares Expires 2031-02-15 F2 · derivative.exercise_date: The option becomes fully exercisable on February 15, 2022. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 02:47 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 5,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-21-000017 · edgar.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,396 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.